The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Pfizer's former CEO and Chair Ian Read and ex-CFO Frank D'Amelio said in a statement that they will not be involved with ...

Starboard said a former CEO and CFO had assisted in its activist campaign but then were pressured to express support for the ...

Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...